Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 60, Issue 10, Pages 6407-6410Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01282-16
Keywords
-
Categories
Funding
- AstraZeneca Pharmaceutical Spain
- Ministerio de Ciencia e Innovacion of Spain, Instituto de Salud Carlos III through the Spanish Network for Research in Infectious Diseases [REIPI RD12/0015, RD16/00016]
- European Regional Development Fund A Way To Achieve Europe ERDF
Ask authors/readers for more resources
The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at <= 4 mu g/ ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant beta-lactam resistance mechanisms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available